サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1434790

抗体生産市場：製品タイプ、プロセス、エンドユーザー別-2024-2030年の世界予測

Antibody Production Market by Antibody Type (Monoclonal Antibodies, Polyclonal Antibodies), Process (Downstream Processing, Filtration, Upstream Processing), End-User - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 188 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
抗体生産市場：製品タイプ、プロセス、エンドユーザー別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 188 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗体生産市場規模は2023年に179億7,000万米ドルと推計され、2024年には201億6,000万米ドルに達し、CAGR 12.40%で2030年には407億7,000万米ドルに達すると予測されます。

抗体生産の世界市場

主な市場の統計
基準年[2023］ 179億7,000万米ドル
予測年[2024］ 201億6,000万米ドル
予測年 [2030] 407億7,000万米ドル
CAGR（%） 12.40%
抗体生産 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは抗体生産市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、抗体生産市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-抗体生産市場の市場規模および予測は？

2-抗体生産市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-抗体生産市場における技術動向と規制の枠組みは？

4-抗体生産市場における主要ベンダーの市場シェアは？

5-抗体生産市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 人口における慢性疾患の有病率の上昇
      • 標的療法と個別化医療に対する需要の高まり
      • ヘルスケアインフラの近代化とヘルスケア支出の増加
    • 抑制要因
      • 抗体生産に関連する高コスト
    • 機会
      • 新規植物由来モノクローナル抗体の導入に向けた調査活動を強力に推進
      • がん免疫療法における二重特異性抗体の新たな応用
    • 課題
      • 抗体生産に対する厳格な規制枠組み
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 抗体生産市場抗体の種類別

  • モノクローナル抗体
  • ポリクローナル抗体

第7章 抗体生産市場：プロセス別

  • 下流処理
    • クロマトグラフィー用樹脂
    • クロマトグラフィーシステム
  • 濾過
    • 消耗品と付属品
    • ろ過システム
  • 上流処理
    • バイオリアクター
    • 消耗品

第8章 抗体生産市場：エンドユーザー別

  • 受託調査機関（CRO）
  • 診断研究所
  • 製薬およびバイオテクノロジー企業
  • 調査機関と学術センター

第9章 南北アメリカの抗体生産市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の抗体生産市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの抗体生産市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca PLC
    • Biogen Inc.
    • Bristol-Myers Squibb Company
    • Cell Signaling Technology, Inc.
    • Eppendorf AG
    • F. Hoffmann-La Roche Ltd.
    • Fibercell Systems Inc
    • GE HealthCare Technologies Inc.
    • Genmab A/S
    • GenScript Biotech Corporation
    • Gilead Sciences, Inc.
    • INTEGRA Biosciences AG
    • Merck KGaA
    • Novartis AG
    • Novo Nordisk A/S
    • Pall Corporation
    • Pfizer Inc.
    • ProteoGenix
    • Sanofi S.A.
    • Sartorius AG
    • Teva Pharmaceutical Industries Ltd.
    • The Antibody Company
    • Thermo Fisher Scientific Inc.
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ANTIBODY PRODUCTION MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBODY PRODUCTION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTIBODY PRODUCTION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTIBODY PRODUCTION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTIBODY PRODUCTION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTIBODY PRODUCTION MARKET DYNAMICS
  • FIGURE 7. ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2023 VS 2030 (%)
  • FIGURE 10. ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ANTIBODY PRODUCTION MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. ANTIBODY PRODUCTION MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTIBODY PRODUCTION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTIBODY PRODUCTION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBODY PRODUCTION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTIBODY PRODUCTION MARKET SIZE, BY POLYCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 9. ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 11. ANTIBODY PRODUCTION MARKET SIZE, BY CHROMATOGRAPHY RESINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTIBODY PRODUCTION MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 15. ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION SYSTMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 19. ANTIBODY PRODUCTION MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. ANTIBODY PRODUCTION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. ANTIBODY PRODUCTION MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. ANTIBODY PRODUCTION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. ANTIBODY PRODUCTION MARKET SIZE, BY RESEARCH INSTITUTES & ACADEMIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 97. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 103. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 104. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 109. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 110. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 115. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 116. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 121. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 127. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 128. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 133. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 134. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 139. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 140. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 150. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 152. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 153. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 158. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 159. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 164. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 165. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 170. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 171. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 176. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 177. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 182. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 183. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 188. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 189. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 194. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 195. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 200. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 201. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 206. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 207. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 210. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 212. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 213. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 218. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 219. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 224. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 225. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 230. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 240. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 242. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 243. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 246. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 248. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 249. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 252. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 254. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 255. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 258. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 260. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 261. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 264. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 266. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. ANTIBODY PRODUCTION MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 277. ANTIBODY PRODUCTION MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 278. ANTIBODY PRODUCTION MARKET LICENSE & PRICING
目次
Product Code: MRR-69324464D117

[188 Pages Report] The Antibody Production Market size was estimated at USD 17.97 billion in 2023 and expected to reach USD 20.16 billion in 2024, at a CAGR 12.40% to reach USD 40.77 billion by 2030.

Global Antibody Production Market

KEY MARKET STATISTICS
Base Year [2023] USD 17.97 billion
Estimated Year [2024] USD 20.16 billion
Forecast Year [2030] USD 40.77 billion
CAGR (%) 12.40%
Antibody Production Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antibody Production Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antibody Production Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antibody Production Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Biogen Inc., Bristol-Myers Squibb Company, Cell Signaling Technology, Inc., Eppendorf AG, F. Hoffmann-La Roche Ltd., Fibercell Systems Inc, GE HealthCare Technologies Inc., Genmab A/S, GenScript Biotech Corporation, Gilead Sciences, Inc., INTEGRA Biosciences AG, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pall Corporation, Pfizer Inc., ProteoGenix, Sanofi S.A., Sartorius AG, Teva Pharmaceutical Industries Ltd., The Antibody Company, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Antibody Production Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Antibody Type
    • Monoclonal Antibodies
    • Polyclonal Antibodies
  • Process
    • Downstream Processing
      • Chromatography Resins
      • Chromatography Systems
    • Filtration
      • Consumables & Accessories
      • Filtration Systms
    • Upstream Processing
      • Bioreactors
      • Consumables
  • End-User
    • Contract Research Organizations (CROs)
    • Diagnostic Laboratories
    • Pharmaceutical & Biotechnology Companies
    • Research Institutes & Academic Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antibody Production Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antibody Production Market?

3. What are the technology trends and regulatory frameworks in the Antibody Production Market?

4. What is the market share of the leading vendors in the Antibody Production Market?

5. Which modes and strategic moves are suitable for entering the Antibody Production Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Antibody Production Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases among population
      • 5.1.1.2. Growing demand for targeted therapies and personalized medicines
      • 5.1.1.3. Modernization of healthcare infrastructure and increase in healthcare expenditure
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with antibody production
    • 5.1.3. Opportunities
      • 5.1.3.1. Robust research activities to introduce novel plant-made monoclonal antibody
      • 5.1.3.2. Emerging applications of bispecific antibodies in cancer immunotherapy
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory frameworks for antibody production
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Antibody Production Market, by Antibody Type

  • 6.1. Introduction
  • 6.2. Monoclonal Antibodies
  • 6.3. Polyclonal Antibodies

7. Antibody Production Market, by Process

  • 7.1. Introduction
  • 7.2. Downstream Processing
    • 7.3.1. Chromatography Resins
    • 7.3.2. Chromatography Systems
  • 7.3. Filtration
    • 7.4.1. Consumables & Accessories
    • 7.4.2. Filtration Systms
  • 7.4. Upstream Processing
    • 7.5.1. Bioreactors
    • 7.5.2. Consumables

8. Antibody Production Market, by End-User

  • 8.1. Introduction
  • 8.2. Contract Research Organizations (CROs)
  • 8.3. Diagnostic Laboratories
  • 8.4. Pharmaceutical & Biotechnology Companies
  • 8.5. Research Institutes & Academic Centers

9. Americas Antibody Production Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antibody Production Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antibody Production Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. AbbVie Inc.
    • 13.1.2. Amgen Inc.
    • 13.1.3. AstraZeneca PLC
    • 13.1.4. Biogen Inc.
    • 13.1.5. Bristol-Myers Squibb Company
    • 13.1.6. Cell Signaling Technology, Inc.
    • 13.1.7. Eppendorf AG
    • 13.1.8. F. Hoffmann-La Roche Ltd.
    • 13.1.9. Fibercell Systems Inc
    • 13.1.10. GE HealthCare Technologies Inc.
    • 13.1.11. Genmab A/S
    • 13.1.12. GenScript Biotech Corporation
    • 13.1.13. Gilead Sciences, Inc.
    • 13.1.14. INTEGRA Biosciences AG
    • 13.1.15. Merck KGaA
    • 13.1.16. Novartis AG
    • 13.1.17. Novo Nordisk A/S
    • 13.1.18. Pall Corporation
    • 13.1.19. Pfizer Inc.
    • 13.1.20. ProteoGenix
    • 13.1.21. Sanofi S.A.
    • 13.1.22. Sartorius AG
    • 13.1.23. Teva Pharmaceutical Industries Ltd.
    • 13.1.24. The Antibody Company
    • 13.1.25. Thermo Fisher Scientific Inc.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing